Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.

NCT00920868 is registered in ClinicalTrials.gov with Herbert Hurwitz, MD as lead sponsor.

NCT NCT00920868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00920868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.
Lead sponsor
Herbert Hurwitz, MD
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2009
Completion date
August 31, 2014
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, solid tumor